FXR inhibition reduces ACE2 expression, SARS-CoV-2 infection and may improve COVID-19 outcome
T. Brevini, M. Maes, G. J. Webb, W. T. H. Gelson, S. Forrest, P. Mlcochova, S. Dillon, S. Varankar, M. Darvish-Damavandi, V. L. Mulcahy, R. E. Kuc, T. L. Williams, V. Galanakis, M. Vila-Gonzalez, O. C. Tysoe, , F. Sampaziotis
This study shows FXR inhibition lowers ACE2 expression, reduces SARS-CoV-2 infection, and correlates with better clinical outcomes in COVID-19.
bioRxiv · Jun 6, 2021 · PreprintMicrobiology